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ratio: 2,43; 65-74 yrs old: 4,72%,I$ 25968, age ratio: 1,31; 75-84 yrs old: 8,45%; I$ 15471, age 
ratio: 0,78; 85+ yrs old: 14,09%, I$ 7832, age ratio: 0,39), and sex, males (47,4%) had a I$: 
22679 (M/F I$ ratio: 1,45). In 1 adm.(53% of deaths), mean cost was I$ 23 792; while ReH 
≤ 365 days (47% of deaths), I$ 13 530, cost ratio ReH/1 adm= 0,57 ; and if ReH < 30 days 
(29,5%), I$ 12354, cost ratio ReH< 30/1 adm= 0,52. ConClusions: Understanding the 
economic burden of dying helps promote better and cost-effective ways of promoting 
palliative care, old and readmitted deaths are less costly.
HealtH Care Use & PoliCy stUdies – regulation of Health Care sector
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From “GeneriC sCHeme” to “Brand-GeneriC sCHeme”: tHe eFFeCt oF new 
PoliCy (2003-2004) on eFFiCienCy oF iranian PHarmaCeUtiCal indUstry
Hashemi Meshkini A.1, Varmaghani M.1, Yousefi M.2, Yaghoubifard S.1, Zekri H.3, 
Kebriaeezadeh A.1
1Tehran University of Medical Sciences, Tehran, Iran, 2Tarbiat-Modarres University of Medical 
Sciences, Mashhad, Iran, 3Allameh-Tabatabaee University of Human Sciences, Tehran, Iran
objeCtives: Brand-Generic scheme was implemented in Iran to improve the compe-
tition in the market. In this study we aim to assess if this new policy has had any posi-
tive effect on efficiency of Iranian pharmaceutical companies. Methods: We used 
Data Envelopment Analysis (DEA) to evaluate the relative efficiency of pharmaceutical 
companies for the years 1999-2008. The Wilcoxon matched-pairs signed-rank test and 
also sign test were used to assess the difference between mean relative efficiency of 
companies before and after policy. Results: Although the Wilcoxon matched-pairs 
signed-rank test did not show any significant difference between before and after 
new policy in term of both technical and pure (managerial) efficiency of included 
companies (Pvalue: 0.079 and 0.07, respectively) but the one–sided sign test indicated 
that only relative pure (managerial) efficiency has improved after this policy (Pvalue: 
0.031). ConClusions: The “Brand-Generic scheme” does not seem to be enough 
policy to improve efficiency of pharmaceutical companies in Iran. To achieve this aim, 
paying special attention to infrastructural requirements including non-discriminating 
and transparent laws and regulations for supporting competition, the competitive 
pricing policies, the presence of international companies in the market and full pri-
vatization of companies had to be also considered by policy makers.
PHP57
reGUlatinG tHe aCCess to an adeqUate and an inteGral assistanCe 
in Brazilian Private HealtH Plans
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
objeCtives: To describe the main actions promoted by the The Federal Regulatory 
Agency for Private Health Insurance and Plans (ANS) to regulate the access 
of private health plans beneficiaries to an adequate and an integral assis-
tance. Methods: A retrospective analysis of data about coverage in health plans 
since ANS creation (1999) was done to identify the main actions promoted by the 
agency in this area. It included the set of rules published and ANS periodic publi-
cations. Results: A very important identified mechanism that ANS employs for 
regulating the users access to a full assistance is the elaboration of a list of medical 
procedures. This list constitutes the minimum obligatory coverage for all plans. It 
is periodically reviewed and incorporations and/or exclusions are made according 
to some precepts like: clinical evidence, epidemiological relevance, among oth-
ers. The guidelines implementation is another important instrument identified 
in this study to the improvement of private health assistance. ANS established a 
collaboration term with the Brazilian Medical Association (AMB) to develop guide-
lines, to spread and to monitor their implementation. ConClusions: The actions 
presented are the main one promoted by ANS to regulate the access to an ade-
quate and an integral assistance. They can also improve the sector efficiency along 
with the rational use of techniques and medical technologies. The instruments 
discussed will be a guide to upgrade the health plans management and their 
efficiency. The patients will have safer end more effective treatments and ANS 
keeps the balance and promotion of health in private health with a new model.
PHP58
a mediação de ConFlitos na ação FisCalizatoria do setor de saúde 
sUPlementar Brasileiro
Tanaka F.H.R., Franco S.
ANS - Brazilian Private Health Regulatory Agency, Rio de Janeiro, Brazil
objetivos: Demonstrar a eficácia da utilização de meios consensuais de mediação 
de conflitos pela Administração Pública no controle e fiscalização do cumprimento 
das normas que regulam a assistência suplementar à saúde no Brasil. Métodos: 
Desde 2010, a ANS – Agência Nacional de Saúde Suplementar implementou o procedi-
mento NIP (Notificação de Investiação Preliminar), cujo objetivo é realizar a mediação 
de conflitos entre operadoras de planos de saúde e consumidores, no que tange a 
situações que envolvem negativa de cobertura assistencial. A NIP é um processo 
totalmente eletrônico, que confere maior celeridade e eficácia na resolução das rec-
lamações dos consumidores, induzindo uma melhora na relação operadora/consu-
midor. Com a NIP, as operadoras têm prazo de 5 dias para solucionar o conflito junto 
ao beneficiário e responder à ANS sobre as medidas tomadas. Após processamento na 
NIP, a reclamação pode ser finalizada por inexistência de infração, reparação de con-
duta ou encaminhada para abertura de processo administrativo, nos casos em que o 
conflito não foi resolvido. ResultAdos: Desde sua implementação, a resolutividade 
dos conflitos na NIP manteve-se acima de 70% do total de reclamações recebidas, o 
que em 2012 significou a conclusão de 42.672 das 54.412 denúncias de negativa de 
cobertura assistencial (78,4% de resolutividade). Antes de seu advento, as reclamações 
eram analisadas por meio de instituição de processo administrativo sancionador, que 
duravam, em média, 18-24 meses para sua conclusão, podendo levar ao arquivamento 
da denúncia ou lavratura de auto de infração contra a operadora. ConClusões: A 
NIP conferiu maior eficácia ao processo fiscalizatório da ANS, proporcionando maior 
to be concentrated among the rich in both years. Decomposition indicated that 
“illegitimate” factors remained large contributors to income-related inequality in 
SRHS even after the equity-centered reform of 2005. ConClusions: Findings sug-
gest that income-related inequality in SRHS might have decreased in Chile after 
the health care reform. Beyond this observed difference over time, the remaining 
inequality is still largely due to illegitimate factors that should be tackled through 
broader policies in the country.
HealtH Care Use & PoliCy stUdies – quality of Care
PHP53
PerCePtion oF Users oF drUG distriBUtion ProGram in Brazil
Carraro W.H., Mengue S.S., Haddad E.W.
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
objeCtives: To characterize the users of access to medicines program developed 
in Brazil, known as Aqui Tem Farmácia Popular Program (PAFP), by identifying those 
users who migrated from other supply of basic medicines programs by means of a 
survey explicitly developed for this purpose. This work also seeks to evaluate the 
meeting customers’ needs by the Program and its satisfaction level. Methods: The 
survey instrument used gathering the users of Aqui Tem Farmácia Popular program 
has been applied in 15 counties from 14 Brazilian states. 1073 interviews com-
posed the sample, in 27 establishments of private pharmacies, during august 2012. 
The collection instrument was composed by three blocks: questions concerning 
the use of the PAFP and other programs of medicines supply; user’s profile infor-
mation; and identification of the medicine supplied. Results: The evaluation of 
the users migration from other programs identified that, before the PAFP, 52% of 
interviewed users was buying the medicines in the private pharmacy and more 
than 30% was using the Public Service in a Health Center of SUS, a piece of 11% 
began the treatment after the PAFP. More than 58% of users would use the service 
of the SUS if there was no PAFP. However, 36% of users reported that they would 
not use the SUS system for withdrawal of medicines. It was observed that 61% of 
users gave out to be economizing while withdrawing the medicines with gratuity 
or at a discount. ConClusions: The conducted survey made possible to character-
ize the users of PAFP showing aspects concerning the participation and the range 
of the program. Generally, it was found that the persons are satisfied and they 
reported to have saved with the program. They also pointed out the convenience 
they have with the possibility of the access to the medicine in any pharmacy with 
the PAFP.
PHP54
a nationwide sUrvey on Patient saFety CUltUre in JaPan
Hirose M.1, Egami K.2, Tsuda Y.2, Honda J.2, Shima H.2
1Shimane University Hospital, Izumo, Japan, 2St. Mary’s Hospital, Kurume, Japan
objeCtives: To explore safety culture dimensions among health care professionals 
using Hospital Survey on Patient Safety Culture (HSOPSC) by developed by AHRQ 
(Agency for Healthcare Research and Quality). Methods: We surveyed nationwide 
the situation of patient safety culture in 13 hospitals (5,760 persons) allowed for 
additional costs on patient safety countermeasures under the social insurance med-
ical fee schedule. The questionnaire consists of seven unit-level aspects of safety 
culture including 24 items, three hospital-level including 11 items, and four outcome 
variables including nine items. Results: An average number of beds was 360 beds 
(63 - 1,354 beds). With regard to ownership, 13 hospitals included three municipality 
and local incorporated agency hospitals, one public hospital, two juridical person 
with social insurance hospitals, six medical corporation hospitals, and one other 
hospital. Number of all respondents was 5,118 persons (response rate: 88.9%), and 
included 295 physicians (90.8%), 2,909 nurses (95.5%), and 146 pharmacists (96.7%). 
In terms of 12 dimensions, the overall average positive response rate (RR) for the 
12 patient safety dimensions of the HSOPS was 49.2%, extremely lower than the 
average positive RR for the AHRQ data (61%). In terms of health care professionals, 
the overall average positive RR for pharmacists (46.2%) was lower than that for 
physicians and nurses (49.6% and 49.4%).With regard to pharmacists, the aver-
age positive RRs for 8 dimensions of the 12 dimensions were the lowest among 
three professionals, and three average positive RRs were the highest; Frequency of 
event reporting (pharmacists: physicians: nurses= 73.6%:53.3%:67.9%), Non-punitive 
response to error (48.8%:42.6%:40.4%), and Staffing (29.1%:27.0%:25.4%). ConClus
ions: The HSOPSC measurement provides the evidence for assessment of patient 
safety culture in Japan’s hospitals. This result that patient safety culture has been 
in a state of development, compared with the US hospitals.
PHP55
Cost and qUality oF dyinG in HosPital: resUlts From tHe arGentine-
HealtH Care Cost and Utilization ProJeCt (a-HCUP)
Insua J.T.1, Villalon R.1, Giunta D.2, Ioli P.3
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de 
Buenos Aires, Caba, Argentina, 3Hospital Privado de la Comunidad, Fundacion Medica de Mar del 
Plata, Mar del Plata, Buenos Aires, Argentina
objeCtives: Little is known about dying in Argentina, we studied costs and readmis-
sions (ReH) < 30 days of hospital dying adults. Methods: A cross sectional study of 1 
year hospital discharges, with HCUPs methods, of patients ≥ 19 yrs old. We obtained 
deaths, first admission (1 adm) and ReH ≤ 365 days and ReH < 30 days; total direct 
medical cost (TC I$), mean (I$) (SD), median I$ (Q1-Q3) discharge cost, (in I$ PPP, 2008), 
stratified by age/sex, admissions and ReH < 30 days and < 365 days. Results: Total 
mortality for ≥ 19 yrs old patients was 4,70%. Among 2137 deaths, Total cost of those 
dead in hospital, TC I$: 40 540 842 ; mean cost per discharge (I$) was 19853 (SD 45 599); 
Median cost per discharge I$ 4182; (Q1: 1452-Q3: 17730 I$), comprising 8,31 % of TC I$. 
Among 43321 discharges, TC$ of those alive, TC: 447 300 754 I$; mean cost per discharge 
($) was 10569 I$ (SD 21 217); Median cost per discharge 14 091 I$; (Q1: 2 496- Q3:10 054 
I$). Relative dead /alive I$ was 1,88 times higher. Mean discharge cost of deceased 
stratified by age group (mortality 19-64 yrs. old: 1,52%, I$ 48332, age 19-64/≥ 19 yrs old 
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age of NIPs of individual/family plans, compared to collective ones, may be a reflec-
tion of a greater weakness in consumer-provider relationship in this type of contract.
PHP62
Poder PoPUlar y reGUlaCión del PreCio de los mediCamentos en 
venezUela
Adesso G.
Universidad Central de Venezuela, Caracas, Venezuela
objeCtivos: Explorar el rol del Poder Popular en el proceso de regulación del precio 
de los medicamentos en Venezuela, articulado por la Superintendencia Nacional de 
Costos y Precios (SUNDECOP) en conformidad con lo establecido en la Ley de Costos 
y Precios Justos y las Providencias Administrativas relacionadas. MetodologíAs: 
Estudio exploratorio documental basado en la búsqueda y revisión de los artículos 
de prensa disponibles y publicados en la página Web oficial de la SUNDECOP. La 
búsqueda y recuperación de la información fue realizada el 10 de marzo de 2012. 
Se tomaron en cuenta para la revisión los artículos que incluían en su contenido 
las palabras: participación o poder popular y regulación del precio de medicamen-
tos. ResultAdos: Se identificaron 172 artículos noticiosos publicados desde 13 julio 
2011 hasta 27 de febrero de 2013. Se revisaron 12 artículos de prensa que cumplían 
con el criterio de inclusión. El 50% de los artículos revisados resaltan la participación 
del Poder Popular en la definición de las políticas de precios y los criterios a tomar 
en cuenta por el Sistema Nacional Integrado de Costos y Precios para la fijación del 
precio de medicamentos, mientras que en 10 de los artículos se desprende el papel del 
Poder Popular como controlador social para vigilar el cumplimiento de la regulación 
una vez sea decretada por la SUNDECOP. ConClusiones: Además de las eventuales 
acciones de inspección y fiscalización, el Poder Popular en Venezuela está aportando 
insumos a la SUNDECOP que serán incorporadas en el proceso de tomas de decisiones 
para fijar el precio a los medicamentos durante el año 2013. Se sugiere profundizar 
en un posterior estudio para conocer y analizar cómo y en qué medida esos aportes 
del Poder Popular están siendo incluidos en el análisis metodológico para establecer 
la definitiva regulación del precio de los medicamentos.
HealtH Care Use & PoliCy stUdies – Conceptual Papers
PHP63
novel PriCinG strateGies to sUPPort sUstainaBle aCCess to mediCine 
in latin ameriCa
Shankar R., Lindon L., Hooper J., Rowbottom R.C.
IMS Consulting Group, Cambridge, UK
With lower returns from price pressures in developed markets, it is imperative for 
pharma companies to seek growth in emerging markets such as Latin America. 
Simultaneously, with rising incomes, a growing middle class in emerging markets 
is increasing demand for access to innovative medicine, especially in diseases such 
as oncology, CV and diabetes. Achieving commercial expansion as well as increasing 
access to innovative medicine in Latin America needs new pricing strategies and fund-
ing models. We discuss and evaluate alternative pricing strategies and funding models 
to support commercial expansion and increase access to innovative medicines in Latin 
American markets such as Brazil, Argentina, Mexico and Colombia. These include cur-
rent industry strategies, equitable pricing strategies and strategies focused on local 
market conditions. We model the impact of these strategies on both specialty and 
primary care medicines. The modelling is based on insights and assumptions drawn 
from analogue analysis in pharmaceuticals and other industries. It is supplemented by 
interviews with industry experts in Latin American market strategies. For the modelling 
we assume current market and public and private insurance coverage structures. We 
find that in primary care medicines there is considerable opportunity for commercial 
and access gain through more differentiated pricing strategies. These strategies are 
more commercially (revenue and profit) optimal than current industry strategy. At the 
same time, they are also access optimal in terms of the eligible patients they provide 
access to. In the case of specialty medicines, differential pricing strategies can increase 
commercial potential, but there is a gap between commercially optimal and access opti-
mal strategies. This gap can be bridged through increased financing for these medicines. 
Based on this analysis, we suggest a path forward in which pharmaceutical companies 
can collaborate with governments and other stakeholders to achieve increased access 
to innovative medicines in a commercially sustainable manner.
PHP64
aCCess to mediCines index: measUrinG How well CoUntries Provide 
aCCess to mediCines
Shankar R.1, Hickson S.1, Gorokhovich L.2
1IMS Consulting Group, Cambridge, UK, 2IMS Consulting Group, London, UK
Developing countries are now following the steps of developed countries in imple-
menting universal health coverage. Health care systems and policies differ across 
countries resulting in various levels of medicine access. To evaluate which systems 
and policies lead to better access, we need a measure to compare how well countries 
provide access to medicine for their populations. Using IMS proprietary data as well 
as public sources, our analysis proposes a Country Access to Medicines Index that 
compares and ranks countries on access to medicine outcomes across four pillars: 
medicine reimbursement coverage, time to reimbursement, medicine affordability 
and support for innovation. Medicine reimbursement coverage measures private 
or public insurance cover for a representative basket of medicines across major 
communicable and non-communicable diseases. It has three components: share of 
population covered, share of medicines covered and share of costs covered. The time 
to reimbursement pillar measures average time to reimbursement for the selected 
basket. The affordability pillar measures relative cost of medicine basket compared 
to the international average both in absolute terms and as a share of per capita GNI 
in each country. The innovation pillar measures local patents and investment in 
R&D. We used this index to compare and rank more than 30 developed and devel-
oping countries. We then look at the policies in these countries to identify features 
that lead to better index scores. We find that five broad factors can help explain 
satisfação aos beneficiários de planos de saúde. Os dados obtidos na NIP são utilizados 
para monitoramento da garantia de atendimento e acesso às coberturas obrigatórias, 
que podem gerar a suspensão de comercialização dos planos identificados com falhas 
assistencias, bem como instauração de regimes especiais de recuperação pela ANS.
PHP59
ConstrUCCión de Un modelo de PriorizaCión aPliCaBle a 
latinoamériCa – el Caso de ColomBia
Avila A.1, Verbel A.1, Castro H.1, Mejia A.1, Sarria A.2
1Instituto de Evaluación Tecnológica en Salud - IETS, BOGOTÁ, Colombia, 2Agencia Española de 
Evaluación de Tecnologías Sanitarias (AETS) del Instituto de Salud Carlos III, MADRID, Spain
objeCtivos: Los sistemas de salud deben enfrentar el desafío de hacer uso eficiente 
de recursos limitados ante necesidades crecientes de salud. Colombia no ha sido ajena 
a éste desafío. El Ministerio de Salud ha entendido la importancia de articular un 
sistema de salud que incorpore un sistema de priorización del gasto sistemático, trans-
parente y legítimo. En el marco de lo anterior, fue creado el “Instituto de Evaluación 
Tecnológica en Salud (IETS)”, que tiene como objetivo proporcionar recomendaciones 
sobre tecnologías en salud y mejores prácticas, basadas en evidencia, para el gobierno 
nacional y demás actores, como insumo para la toma de decisiones. En este proceso, 
uno de los primeros pasos es diseñar un proceso para la priorización y selección 
de tecnologías a evaluar. MetodologíAs: A partir de una revisión de diferentes 
metodologías de priorización, se propuso un mecanismo de análisis de decisión de 
múltiples criterios, que fue discutido en panel de expertos del gobierno y otros actores. 
Se realizó un piloto de priorización que permitió detectar los principales riesgos y 
desafíos en cada etapa del proceso. A partir de la discusión, construcción colectiva y 
experiencia del piloto, se seleccionaron, definieron y ponderaron los criterios de pri-
orización, y se diseñaron las diferentes etapas e instrumentos para llevar a cabo el pro-
ceso. ResultAdos: Los criterios seleccionados fueron la gravedad de la enfermedad, 
la población afectada, el costo de adquisición de la tecnología, la atención a grupos vul-
nerables, el interés de salud pública y la solicitud de la ciudadanía. ConClusiones: 
Emplear criterios explícitos facilita que la priorización sea un proceso legítimo y trans-
parente. La propuesta permitirá al Ministerio de Salud, como líder del proceso con el 
concurso de otros actores, contar con herramientas para priorizar y seleccionar tec-
nologías para evaluación. La experiencia colombiana dará herramientas metodológicas 
a otros países interesados en la construcción de este tipo de procesos.
PHP60
tHe notiFiCation oF Preliminary investiGation (niP) oF tHe Federal 
reGUlatory aGenCy oF Private HealtH and insUranCe and Plans 
(ans): a tool to FaCilitate tHe aCCess to tHe mandatory CoveraGe
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
objeCtives: To describe the instrument NIP (Notification of Preliminary 
Investigation) and it’s role on solving conflicts related to the obligatory cover-
age access, between health plans and patients. Methods: A critical analysis of 
the rule that created NIP (Regulatory Resolution nº 226/2010), established by The 
Federal Regulatory Agency for Private Health Insurance and Plans (ANS), was done to 
characterize the tool. Results: The Notification of Preliminary Investigation (NIP) 
consists of a communication time to mediate the relationship between consumers 
and providers of health plans in cases of unauthorized procedures by the provider. 
NIP is an electronic process to solve the conflicts before a process that can lead to 
the punishment of the health plan provider. A contact is previously made to notify 
the health plan provider about the problem and it has five business days to answer 
it. This way, the health plan provider has the opportunity to solve the question 
without punishment and the beneficiaries can have a faster access to the procedure 
prescribed by the doctors. If the procedure doesn’t have coverage according to the 
supplementary health rules (it is not listed on ANS Medical List of Procedures), the 
demand is filed. If the provider’s answer is not enough to conclude the question, 
it’s sent to the Inspection Department to a more detailed analysis before being fin-
ished. ConClusions: The NIP is a mediation instrument that can help ANS to solve 
the problems between beneficiaries and health plan providers, giving a fast answer 
to both interested actors of the process. It can be positive because sometimes the 
questions are solved without the provider punishment and the beneficiaries’ injury. 
The conflict mediation by NIP can contribute to the change in the entities attitude 
and culture and can also promotes the interaction and the active participation of 
the actors involved.
PHP61
tHe qUalitative ProFile oF tHe CoveraGe ComPlaints made By HealtH 
Plan Users to tHe Federal reGUlatory aGenCy For Private HealtH 
insUranCe and Plans (ans)
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
objeCtives: To define the qualitative profile of the coverage complaints made by 
health plan users, to The Federal Regulatory Agency for Private Health Insurance and 
Plans (ANS). Methods: A retrospective analysis of the Notification of Preliminary 
Investigation (NIP) registers in 2011 and in the first half of 2012 was performed. The 
data were extracted from Inspection System (SIF). The variables considered were: the 
subject of the coverage complaints (Medical List of Procedures, Time for Coverage 
Access, Managed Care, etc.), the date of the contract (before or after ANS regulation) 
and the type of the plan (individual/ family or collective). Results: The study shows 
a change on predominant coverage subject: In 2011 43,5 % of the complaints were 
about “ Medical List of Procedures”. In 2012, the main subject was “Time for coverage 
access” (36,2% of he coverage complains).” It was possible to verify that, in both years 
considered, there was a prevalence of ANS regulated contracts of individual/familiar 
type (44.8% in 2011 and 47.7% in 2012). ConClusions: This study helped to know the 
qualitative profile of the coverage complaints in brazilian supplementary health. The 
increased number of complaints about “Time for coverage access” in 2012 may indicate 
that the services offered are not being enough to attend the users. The higher percent-
